By a News Reporter-Staff News Editor at Drug Week -- New research on Drugs and Therapies is the subject of a report. According to news reporting originating from Tucson, Arizona, by NewsRx correspondents, research stated, "The aim of this study was to design and develop respirable antibiotics moxifloxacin (MOXI) hydrochloride and ofloxacin (OFLX) microparticles and nanoparticles, and multifunctional antibiotics particles with or without lung surfactant 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) for targeted dry powder inhalation delivery as a pulmonary nanomedicine. Particles were rationally designed and produced by advanced spray-drying particle engineering from an organic solution in closed mode (no water) from dilute solution."
Our news editors obtained a quote from the research from the University of Arizona, "Scanning electron microscopy indicated that these particles had both optimal particle morphology and surface morphology, and the particle size distributions were suitable for pulmonary delivery. Comprehensive and systematic physicochemical characterization and in vitro aerosol dispersion performance revealed significant differences between these two fluoroquinolone antibiotics following spray drying as drug aerosols and as cospray-dried antibiotic drug: DPPC aerosols. Fourier transform infrared spectroscopy and confocal Raman microspectroscopy were employed to probe composition and interactions in the solid state. Spray-dried MOXI was rendered noncrystalline (amorphous) following organic solution advanced spray drying. This was in contrast to spray-dried OFLX, which retained partial crystallinity, as did OFLX: DPPC powders at certain compositions. Aerosol dispersion performance was conducted using inertial impaction with a dry powder inhaler device approved for human use."
According to the news editors, the research concluded: "The present study demonstrates that the use of DPPC offers improved aerosol delivery of MOXI as cospray-dried microparticulate/nanoparticulate powders, whereas residual partial crystallinity influenced aerosol dispersion of OFLX and most of the compositions of OFLX: DPPC inhalation powders."
For more information on this research see: Design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery. International Journal of Nanomedicine, 2013;8():3489-3505. International Journal of Nanomedicine can be contacted at: Dove Medical Press Ltd, PO Box 300-008, Albany, Auckland 0752, New Zealand (see also Drugs and Therapies).
The news editors report that additional information may be obtained by contacting J.H. Duan, University of Arizona, Coll Pharm, Skaggs Center Pharmaceut Sci, Tucson, AZ 85721, United States. Additional authors for this research include F.G. Vogt, X.J. Li, D. Hayes and H.M. Mansour.
Keywords for this news article include: Antibacterial, Antibiotics, Antimicrobials, Tucson, Arizona, Ofloxacin, Quinolones, Moxifloxacin, United States, Topical Agents, Otic Preparations, Drugs and Therapies, Otic Antiinfectives, Ophthalmic Preparations, North and Central America, Ophthalmic Antiinfectives
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC